Unitrac

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Unitrac

Property Description
Active Ingredient Itraconazole
Form Capsules, Oral Solution, Tablets
Pharmacological Class Triazole Antifungal Agent
Common Use Treatment of systemic and deep-seated fungal infections
Origin Synthetic

Unitrac is a systemic, prescription-only pharmaceutical product containing the active substance Itraconazole, a powerful synthetic triazole antifungal agent. The medication is administered exclusively via the oral route for absorption throughout the body, making it suitable for treating infections beyond the skin surface. Pharmacological data confirm that Itraconazole is effective against a broad spectrum of fungal species, supporting its use for serious fungal diseases.


Unique Features and Classification

Itraconazole is specifically categorized as an azole antifungal, belonging to the more advanced subclass of triazole derivatives. This classification is clinically recognized for its targeted mechanism against fungal pathogens. The drug achieves its therapeutic purpose by interfering with the fungus's ability to produce ergosterol, a molecule vital for maintaining the structural integrity of the outer cell membrane. This interruption compromises the fungus's ability to grow, which is key to controlling the spread of infection. For instance, it is commonly utilized for prolonged treatment regimens against infections like histoplasmosis and blastomycosis.


Composition and Available Forms

For administration, Unitrac is supplied in several distinct dosage forms, including capsules, tablets, and an oral solution (liquid). The existence of varied formulations is important because the oral solution formulation is known to have specific absorption characteristics compared to the solid forms. All preparations require various pharmaceutical excipients to stabilize the active substance, Itraconazole, and optimize its delivery, ensuring a consistent effect against deep-seated or systemic fungal threats.

Regulatory References

  1. Itraconazole - StatPearls - NCBI Bookshelf
  2. Itraconazole: MedlinePlus Drug Information

What side effects are possible with Unitrac?

Possible Side Effects and Safety Information

The safety profile for Unitrac (Itraconazole) is defined by officially documented adverse reactions categorized by frequency and the body systems affected. These classifications are established in governmental regulatory documents, such as those from the FDA and EMA.


Key Regulatory Safety Classifications

Category Examples (as documented in official labels)
Most Common Reactions Nausea, vomiting, diarrhea, abdominal pain, headache, rash, edema, fatigue, and fever.
System-Organ Classes Effects documented across Gastrointestinal, Hepatobiliary, Nervous System, Cardiovascular, and Skin systems.

Serious Adverse Reactions

The medication carries specific regulatory warnings for rare but serious adverse reactions. These include the potential for Serious Hepatotoxicity (liver injury, including fatal liver failure) and the risk of Congestive Heart Failure (CHF) or worsening pre-existing ventricular dysfunction.

Severe dermatologic reactions, such as Stevens-Johnson syndrome, and Cardiac Dysrhythmias (e.g., Torsades de Pointes when co-administered with certain drugs) are also noted in official labeling.


Safety Patterns and Restrictions

Regulatory documents highlight that some serious effects, such as hepatotoxicity, have been reported within the first week of treatment. Conversely, Peripheral Neuropathy is an effect reported predominantly during long-term exposure. Safety restrictions include a contraindication for use in patients with evidence of ventricular dysfunction for non-life-threatening conditions, given the drug's documented negative inotropic effect (decreased cardiac contractility).

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose is primarily characterized by the manifestation of severe systemic toxicities detailed in regulatory warnings, reflecting dangerously high exposure to the active substance. This exposure can involve multiple physiological systems.

Documented Overdose Profile

Manifestation Severity and Action
Cardiovascular/Hepatic Signs Signs of Congestive Heart Failure (CHF), Ventricular Dysfunction, or clinical signs consistent with liver disease (e.g., jaundice, fatigue, abdominal pain).
Life-Threatening Outcomes Fatal Acute Liver Failure, Torsades de Pointes (a potentially fatal arrhythmia), and Sudden Death are documented serious outcomes associated with high systemic exposure.

Regulator-Mandated Emergency Actions

The regulatory labeling requires immediate discontinuation of administration if signs or symptoms of Congestive Heart Failure or Liver Disease are observed. Urgent medical attention must be sought to manage these severe clinical presentations, which may also include symptoms like Peripheral Neuropathy or Hearing Loss. Patients with Hepatic Impairment have a significantly prolonged elimination half-life, which elevates the potential for sustained toxic exposure.

In an overdose scenario, official guidance confirms that no specific antidote is known. Treatment is consequently limited to supportive measures due to the drug's characteristics. Regulatory information confirms Itraconazole is not removed by dialysis, constraining procedural options for managing high-exposure toxicity.

Therapeutic Uses of Unitrac

What Unitrac Treats — Main Uses and Benefits

Unitrac (Itraconazole) is a prescription antifungal agent commonly used to help with managing conditions characterized by periods of heightened symptoms related to fungal proliferation in the body's tissues. Its therapeutic purpose is to support the patient by easing the overall symptom load and managing symptoms related to systemic imbalance associated with fungal growth. It is indicated for both systemic and superficial fungal diseases.

The medication is relevant for managing symptoms that interfere with daily functioning across various conditions, including deep-seated mycoses like Histoplasmosis and Blastomycosis, infections of keratinized tissues such as severe onychomycosis (nail fungus), and mucosal yeast infections like esophageal Candidiasis.

“The primary goal is to provide supportive relief when symptoms become temporarily overwhelming and supports patients during episodes of heightened discomfort.”

In these scenarios, Unitrac assists with maintaining functional stability and contributes to improved comfort by addressing the underlying fungal cause of symptoms like persistent fever, chronic cough, and painful mucosal plaques.


Quick Fact: Relief for Chronic Systemic Distress

The medication is commonly used in clinical settings that involve acute or unstable symptom patterns, where it may assist with managing symptoms related to systemic imbalance, such as generalized fatigue and persistent fever.

Regulatory References

  1. ITRACONAZOLE capsule labeling provided by NIH DailyMed

Eligibility and Restrictions for Use

Who Can and Cannot Use Unitrac?

Unitrac (Itraconazole) eligibility is defined by strict regulatory criteria, primarily related to cardiac function, age, and reproductive status.

Use is contraindicated for patients with current or a history of Congestive Heart Failure (CHF) or ventricular dysfunction, particularly when treating non-life-threatening fungal infections. It is also prohibited in patients with known hypersensitivity to itraconazole. Furthermore, use is contraindicated in women who are pregnant or are planning to conceive for non-life-threatening indications; women of childbearing potential are required to use effective contraception during and for a period after treatment.

The medicine is not recommended for pediatric patients because its safety and efficacy have not been established due to limited clinical data. Use in older adults requires caution, reflecting the higher prevalence of decreased hepatic, renal, or cardiac function in this group.

Conditional use is necessary for patients with hepatic or renal impairment. In patients with liver disease, continued use is strongly discouraged unless the benefit in a life-threatening situation clearly outweighs the risk. Patients with risk factors for CHF must be closely monitored and are eligible only if the benefit clearly outweighs the risk.

What should I know about interactions with other medicines?

Unitrac Interactions with Other Medicines and Products

Unitrac (Itraconazole) has an extensive interaction profile due to its capacity as a strong inhibitor of the Cytochrome P450 3A4 (CYP3A4) enzyme and the P-glycoprotein (P-gp) drug transporter, as documented in regulatory information. This inhibition often leads to significantly increased plasma concentrations of co-administered medicines, potentially resulting in toxicity.

Official Regulatory Prohibitions

Specific combinations are formally contraindicated in regulatory labeling because of the risk of serious adverse events. These include certain antiarrhythmics (e.g., dofetilide, quinidine), lipid-lowering agents (e.g., simvastatin, lovastatin), and ergot alkaloids. Co-administration with these and numerous other drugs (e.g., lurasidone, triazolam, oral midazolam) is strictly prohibited by regulatory authorities.

Administration Constraints and Exposure

The Unitrac capsule formulation requires an acidic environment for proper absorption. Regulatory constraints require a separation of at least 2 hours between the capsule and gastric acid suppressors (e.g., antacids, PPIs) to maintain adequate systemic exposure. Conversely, strong CYP3A4 inducers (e.g., rifampin) are contraindicated as they reduce Itraconazole's efficacy.

Population-Specific Cautions

Official labeling contains specific warnings where interaction severity is heightened. For certain co-administered drugs, such as colchicine or telithromycin, the interaction is classified as prohibited or requires enhanced caution in patients with documented renal or hepatic impairment.

Mechanism of Action

How Unitrac Works: Mechanism of Action

Targeting the Fungal Sterol Synthesis Pathway

Unitrac's primary action begins at the molecular level by inhibiting the fungal enzyme Lanosterol 14alpha-Demethylase (CYP51). The drug molecule coordinates directly with the enzyme's heme iron, blocking a critical step in the ergosterol biosynthesis pathway. This inhibition prevents the fungus from producing ergosterol, a sterol component of its cell membrane.


Disruption of Fungal Cell Membrane Integrity

The enzyme blockade leads to the accumulation of structurally abnormal, methylated sterols inside the fungal cell. The presence of these toxic intermediates, combined with the absence of functional ergosterol, structurally compromises the fungal cell membrane, increasing its permeability and fragility. This molecular failure results in fungistatic activity (growth inhibition) and fungicidal activity (cellular death), depending on drug concentration and exposure time.


Mechanisms of Action Limitation

The drug's mechanism can be challenged by specific molecular defenses developed by the fungus. These limitations include point mutations in the CYP51 gene, which reduce the drug's binding affinity to the target enzyme, and the upregulation of efflux pump transporters, which actively pump the drug out of the fungal cell, diminishing the effective concentration required for enzyme inhibition.

Dosage and Administration Information

Official Administration Guidelines

Unitrac (Itraconazole) is indicated for oral administration via capsule, tablet, or oral solution formulations. To ensure proper drug delivery and absorption throughout the body, administration follows specific protocols established for the medication.


Dosing and Scheduling Principles

Regimen Feature Standard Guidelines
Loading Dose 200 mg three times daily (TID) for the first 3 days (for systemic infections).
Maintenance Dose Typically 200 mg once or twice daily (QD/BID). Doses exceeding 200 mg/day must be administered in two divided doses.
Pulsed Dosing A one-week treatment period followed by a three-week drug-free interval is the regimen for fingernail onychomycosis.
Duration Long-term use is standard; therapy for systemic infections often continues for a minimum of three months and may last up to 12 months or more.

Context-of-Use Requirements

Administration depends on the specific formulation used:

  • Capsules and Tablets must be taken with a full meal to achieve maximal drug absorption, and solid forms must be swallowed whole without crushing or breaking.
  • Oral Solution is best taken on an empty stomach (without food or liquid, other than water) to optimize absorption. If used for oral candidiasis, the dose should be swished in the mouth for several seconds before swallowing.

Technical specifications indicate that the capsule and oral solution formulations are not interchangeable at the same dose due to significant differences in bioavailability. Furthermore, patients with impaired hepatic function require careful monitoring, as the drug's elimination half-life can be doubled in cirrhotic subjects, and decreased drug exposure has been noted in renal impairment.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Unitrac (Itraconazole)

Unitrac (Itraconazole) has been the subject of research across several distinct types of fungal infections. The available evidence describes what has been studied and what remains uncertain.


Evidence for Use in Systemic Fungal Diseases: Histoplasmosis and Blastomycosis

This section will summarize the structure of the clinical research, primarily older prospective trials and subsequent systematic reviews, that contributed to the evidence landscape for Unitrac when exploring internal infections like histoplasmosis and blastomycosis, and what outcomes these studies measured (e.g., mycological status and symptom change).

Research for these deep-seated infections primarily involved prospective, non-randomized open trials in adult populations. The research monitored outcomes related to systemic or functional imbalance, such as changes in fever and outcomes describing inflammatory states. Studies explored recurrence rates over defined time intervals, often spanning six months to one year after treatment was complete.

Certainty remains low in some aspects because the core data largely relies on older, non-randomized trial designs, limiting the ability to draw conclusions from masked, controlled comparisons. There is limited information for long-term outcomes extending beyond the typical post-treatment follow-up period.


Evidence for Use in Onychomycosis (Nail Fungus)

This area will outline the evidence derived from Randomized Controlled Trials (RCTs) and controlled comparative studies, focusing on how different dosing regimens were evaluated and what objective endpoints (e.g., nail clearance) were used to assess the outcome in patients with nail infections.

These RCTs reported measurements of clearance rates in the study populations after a long follow-up period needed to account for the slow growth of the nail. Research explored recurrence rates, which was observed in some studies during extended follow-up periods. A key limitation is that results apply only to the populations studied, and the assessment of "clinical status" can sometimes be subjective. Long-term effects are not fully established regarding recurrence rates extending many years beyond the study period.


What is Still Uncertain in the Research Landscape

A primary limitation across the evidence base for systemic infections is the reliance on non-randomized trials for the foundational data. Additionally, there is a recognized issue that the conventional capsule formulation may be associated with variable absorption, impacting the consistency of drug concentrations in the body and potentially influencing observed outcomes. Finally, research describes that long-term effects are not fully established, particularly concerning the durability of the outcome.

Frequently Asked Questions (FAQ)

Common questions about Unitrac (FAQ)


Q: What are the age restrictions for taking Unitrac?

Official guidance states that Unitrac is not recommended for pediatric patients because its safety and effectiveness have not been established due to limited clinical data. For older adults, caution is advised, as this group may have a higher prevalence of decreased cardiac, hepatic, or renal function, which is a factor noted in the official product information.


Q: What is the likelihood of experiencing a specific side effect, like headache, with Unitrac?

Regulatory documents categorize side effects by frequency. Nausea, vomiting, diarrhea, headache, and rash are typically documented as common reactions in the official safety profile. The full product information provides detailed frequency tables that indicate the reported likelihood of specific side effects.


Q: Are there any foods or beverages, like grapefruit juice or alcohol, that interact with Unitrac?

Regulatory information advises patients to avoid grapefruit juice as it can increase the concentration of the drug in the body, which is noted as potentially raising the risk of certain side effects. Official guidance also generally advises caution regarding the use of alcohol, as it is noted in regulatory information.


Q: How long can a person safely take Unitrac?

The required length of treatment for systemic infections is often long-term, lasting a minimum of three months and sometimes continuing for 12 months or longer. However, regulatory labels note that some effects, such as Peripheral Neuropathy (nerve damage), are reported predominantly during long-term exposure, which is a factor considered during treatment.


Q: What is the purpose of the black box warning on Unitrac's label, if one exists?

The official BOXED WARNING (a key regulatory caution) highlights the risk of Congestive Heart Failure (CHF) and potential Cardiac Effects, especially when administered intravenously. It also warns of serious Drug Interactions, which highlights the potential for serious adverse events when combined with certain other medicines.


Q: Is the effectiveness of Unitrac affected by diet?

Yes. According to official guidelines, the effectiveness of Unitrac is tied to how it is absorbed. The capsule and tablet forms must be taken with a full meal for maximum absorption, while the oral solution is best absorbed when taken on an empty stomach.


Q: Does Unitrac cause weight gain?

According to the official product information, weight change is not documented among the most common adverse reactions listed in the regulatory safety profile of Unitrac.


Q: How long does it typically take before Unitrac starts working?

From a pharmacological perspective, the peak drug concentration in the blood is typically reached within 2 to 5 hours after administration. However, steady-state concentrations (when drug levels are stabilized in the body) are generally achieved within about 15 days of starting repeated dosing.


Q: What is the usual duration of Unitrac's effects after one dose?

The duration of the medicine's presence in the body is measured by its terminal half-life, which generally ranges from 16 to 28 hours after a single dose and is known to increase with repeated daily dosing.


Q: Can Unitrac be taken with over-the-counter pain relievers like ibuprofen?

Unitrac's official interaction lists primarily focus on drugs that inhibit or induce the CYP3A4 enzyme. Regulatory sources do not list ibuprofen as one of the specific medications that is formally contraindicated (strictly prohibited) for co-administration.


Q: Does Unitrac interact negatively with common supplements like multivitamins or herbal remedies?

Regulatory sources advise patients to inform their healthcare provider about all medications, over-the-counter products, and herbal supplements they are taking. This is because certain herbal products and supplements may interact with Unitrac, as the potential for interaction exists.


Q: Does Unitrac affect laboratory blood test results?

Unitrac is associated with the potential for elevated liver enzymes and Serious Hepatotoxicity (liver injury). Due to this risk, official guidance notes that treatment requires regular liver function testing (a type of blood test) to assess the patient’s status during treatment.


Q: Is Unitrac a controlled substance?

No. Official regulatory labeling in the United States indicates that Unitrac is not classified as a controlled substance under the Drug Enforcement Administration (DEA) schedule.


Q: Does Unitrac contain gluten or common allergens?

Official labeling lists the inactive ingredients, such as sucrose and maize starch (corn), which can be checked against known dietary restrictions. Explicit statements regarding general allergens or gluten-free status are not standard in the summary of regulatory data.


Q: Is Unitrac known to cause dependency?

No. Unitrac is not classified as a controlled substance, and regulatory information does not document that it is known to cause physical dependence or has potential for abuse.


Q: What happens if I stop taking Unitrac suddenly?

Regulatory documents state that if signs of serious conditions like congestive heart failure or liver disease appear, the drug should be discontinued. Because of the medicine's long half-life, its concentration in the body decreases slowly over 7 to 14 days after stopping treatment.


Q: Does Unitrac have any warnings related to driving or operating machinery?

Official documents advise caution regarding activities like driving or operating machinery. This is because Unitrac may cause side effects such as dizziness, visual disturbances, or temporary hearing loss.


Q: Is there a generic version of Unitrac available?

Yes, the active ingredient itraconazole is widely available in generic formulations, in addition to the brand-name product.


Q: What if I have high blood pressure; can I still use Unitrac?

Patients with risk factors for congestive heart failure, which includes high blood pressure (hypertension), should use the medication with caution. Official information indicates that this condition may increase the risk for certain serious cardiac side effects.


Q: Is Unitrac known to interact with birth control pills?

Regulatory guidance states that women of childbearing potential are required to use effective contraception during treatment and for a period after the final dose. This is because Unitrac may affect the effectiveness of some birth control methods.


Q: Do patients generally need dose adjustments for Unitrac based on body weight?

Official dosing guidelines for the capsule formulation are generally based on a fixed dosage amount and are not typically adjusted based on body weight for adult patients receiving standard treatment regimens.


Q: Are there any specific lifestyle changes mentioned in official guidance for people taking Unitrac?

Regulatory information advises avoiding grapefruit juice and alcohol, and has specific requirements regarding taking the medicine with or without food. These represent the primary lifestyle-related guidance provided in the official product information.


Q: Are there any known withdrawal symptoms if Unitrac is discontinued?

Regulatory documents do not specifically list withdrawal symptoms after discontinuing Unitrac. After treatment is stopped, the drug concentrations decrease slowly over 7 to 14 days due to its long half-life.


Q: Is Unitrac recommended for use during breastfeeding, according to official guidance?

Limited data suggests Unitrac passes into breast milk in small amounts. Official guidance indicates that an alternate drug may be considered, particularly when nursing a newborn or preterm infant, due to limited clinical information on its effects in these populations.

How should Unitrac be stored and disposed of?

Official Storage Conditions

Unitrac (Itraconazole) must be stored strictly according to its official labeling to maintain stability. The capsules must be kept at controlled room temperature, specifically between 15 C and 25 C (59 F to 77 F). The medication must be protected from light and moisture and stored away from heat.

The oral solution must be stored at or below 25 C and should not be frozen.

Packaging and Child Safety

All Unitrac formulations must be kept in the container that they came in, with the container tightly closed. The medicine has a stability constraint: the oral solution must be discarded 30 days after first opening. A mandatory requirement is to keep Unitrac out of the sight and reach of children.

Disposal Instructions

Unused or expired Unitrac must be disposed of safely. Official guidance instructs against throwing away the medicine via waste water or regular household waste. Disposal must follow government-endorsed protocols, such as medication take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Unitrac found in:

A-Z Index: